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Abstract
Introduction This study was designed to compare the clinical
acceptability of two cardiac output (CO) monitoring systems: a
pulse wave contour-based system (FloTrac-Vigileo) and a
bioreactance-based system (NICOM), using continuous
thermodilution (PAC-CCO) as a reference method.
Methods Consecutive patients, requiring PAC-CCO monitoring
following cardiac surgery, were also monitored by the two other
devices. CO values obtained simultaneously by the three
systems were recorded continuously on a minute-by-minute
basis.
Results Continuous recording was performed on 29 patients,
providing 12,099 simultaneous measurements for each device
(417 ± 107 per patient). In stable conditions, correlations of
NICOM and Vigileo with PAC-CCO were 0.77 and 0.69,
respectively. The bias was -0.01 ± 0.84 for NICOM and -0.01 ±
0.81 for Vigileo (NS). NICOM relative error was less than 30%
in 94% of the patients and less than 20% in 79% vs. 91% and
79% for the Vigileo, respectively (NS). The variability of
measurements around the trend line (precision) was not
different between the three methods: 8 ± 3%, 8 ± 4% and 8 ±
3% for PAC-CCO, NICOM and Vigileo, respectively. CO
changes were 7.2 minutes faster with Vigileo and 6.9 minutes
faster with NICOM (P < 0.05 both systems vs. PAC-CCO, NS).
Amplitude of changes was not significantly different than
thermodilution. Finally, the sensitivity and specificity for
predicting significant CO changes were 0.91 and 0.95
respectively for the NICOM and 0.86 and 0.92 respectively for
the Vigileo.
Conclusions This study showed that the NICOM and Vigileo
devices have similar monitoring capabilities in post-operative
cardiac surgery patients.
Introduction
Until recently, continuous cardiac output (CO) monitoring
required an invasive method, via a pulmonary artery catheter
for thermodilution. During the past decade, several less inva-
sive methods have been proposed [1,2]. Among these tech-
niques, the FloTrac-Vigileo™ which uses arterial pressure
signal monitoring to assess stroke volume, has given interest-
ing preliminary results, but still requires an arterial catheteriza-
tion [3]. A totally Non Invasive CO Monitoring (NICOM™)
device, based on chest bioreactance, has been used in the
majority of patients after cardiac surgery and could be useful
in monitoring critically ill patients [4,5]. We designed this study
to compare the clinical acceptability of the Vigileo™ and
NICOM™ devices in critically ill patients, using semi-continu-
ous thermodilution CO (PAC-CCO) as a reference method.
Methods and materials
Patients
We studied consecutive patients requiring PAC-CCO moni-
toring in the immediate postoperative period following pre-
scheduled cardiac surgery. Patients were treated according to
our standard protocols and no specific intervention was per-
formed for this study. In each patient, a radial arterial catheter
and a PAC-CCO catheter (Edwards Life Sciences, Irvine, CA,
CO: cardiac output; FloTrac-Vigileo™: cardiac output monitoring system based on arterial pressure signal; ICC: Intra Class Correlation; ICU: intensive 
care unit; NICOM™: Non Invasive Cardiac Output Monitoring system based on chest bioreactance; NS: not significant; PAC-CCO: continuous ther-
modilution using a pulmonary artery catheter; r: Pearson correlation coefficient; SaO2: arterial oxygen saturation; SAPS: Simplified Acute Physiologic 
Score; SD: standard deviation; SEM: standard error of the mean; SvO2: mixed venous oxygen saturation; VO2: oxygen consumption.Critical Care    Vol 13 No 3    Marqué et al.
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USA) were inserted preoperatively and maintained in place
during the immediate postoperative period. The correct posi-
tioning of the PAC-CCO was checked by systematic chest x-
rays at 1, 4, and 12 hours postoperatively. Postoperative
echocardiography was systematically performed, to check for
intracardiac shunts and significant tricuspid regurgitation.
The Vigileo™ (Edwards Lifesciences, Irvine, CA, USA) monitor
with software version 1.01 was connected to the radial artery
catheter via the FloTrac™ (Edwards Lifesciences, Irvine, CA,
USA) pressure sensor. This recently introduced system calcu-
lates continuous CO on arterial pressure waveform character-
istics but does not require external calibration. Individual
demographic data, including height, weight, age, gender, and
the real-time arterial pressure waveform analysis, are used to
estimate arterial compliance.
The NICOM™ system (Cheetah Medical, Wilmington, DE,
USA) requires the connection of four double electrode stick-
ers placed on the thorax. Upper stickers were placed across
the mid-left and right clavicles, and lower stickers were placed
across the mid-left and right-last rib. In each electrode pair, the
upper electrode delivers a small alternating current that has
propagation characteristics that are sensed along the thorax
by the lower electrode pairs, thus providing a measure of bio-
reactance (i.e., analysis of the variation in the frequency spec-
tra of a delivered oscillating current that occurs when the
current traverses the thoracic cavity, as opposed to the tradi-
tional bioimpedance, which relies only on analysis of changes
in signal amplitude). This yields a signal-to-noise ratio that is
about 100-fold greater than traditional bioimpedance [6].
Data collection
For each patient, usual demographic data, type of surgery, and
Simplified Acute Physiologic Score (SAPS) II were collected.
Following intensive care unit (ICU) admission, CO values
simultaneously furnished by the PAC-CCO, Vigileo™, and
NICOM™ devices were automatically and almost continuously
recorded using a computer data logger on a minute-by-minute
basis. Periods of time in which one of the three devices gave
unrealistic results for evident technical reasons were elimi-
nated manually. For the reference method, one patient with
severe tricuspid regurgitation was removed. NICOM™ discon-
nection is identified by the system and corresponding data
were eliminated accordingly. For the Vigileo™, we eliminated
periods of time where there was a loss of radial artery signal
identified by a very low CO value equal or close to zero.
Endpoints
Clinical acceptability was defined by four criteria for which we
prospectively determined the tolerances as previously
described [5]. In summary, the new technologies (Vigileo™
and NICOM™) were considered as: acceptably accurate
when bias of measurement was less than 20%; acceptably
precise when random error of measurements around the mean
value were less than 20%; acceptably responsive when time
delay and amplitude of change were at least equivalent to
PAC-CCO, and acceptably reliable when sensibility and sen-
sitivity in detecting simultaneous directional changes in CO
was close to one. For this final criteria, unacceptable discord-
ances in directional changes were defined as a difference of
more than 20% between the two slopes or as a negative Intra
Class Correlation (ICC). Our local institutional review board
approved this protocol. Informed consent was obtained from
each patient.
Data analysis
Estimates were reported as mean ± standard deviation (SD).
Differences in CO were analyzed using a student's t-test when
normally distributed and a Wilcoxon test when abnormally dis-
tributed. A P < 0.05 was considered indicative of an absence
of a type 1 error. For each patient, basic agreement between
NICOM™, Vigileo™, and PAC-CCO was assessed using the
ICC ratio and the Pearson correlation coefficient (r). The bias
and the variability of the differences (NICOM™ vs. PAC-CCO,
Vigileo™ vs. PAC-CCO and Vigileo™ vs. NICOM™) were illus-
trated using the modified Bland and Altman approach [7]. This
traditional approach did not allow for all our predetermined cri-
teria of clinical acceptability to be studied. In particular, preci-
sion is affected by natural CO changes, by the large variability,
and the low time responsiveness of PAC-CCO [8]. To address
these issues, we used the process developed previously [5].
Basically, we distinguished periods of stable, increasing, and
decreasing CO using PAC-CCO slopes for optimal analysis of
our criteria of clinical acceptability. We also studied periods of
time where the application of standard protocols led to a
hemodynamic challenge. Negative challenges were created
when a lung recruitment test was performed and positive chal-
lenges were created by rapid fluid infusion and passive leg ris-
ing. Finally, the potential influence of systolic arterial pressure,
pulmonary systolic artery pressure, and hematocrit (all factors
known to potentially influence these methods) by assessing
the bias and relative error of these three variables.
Results
We studied 29 patients (26 men and 3 women), with a mean
age of 63.2 ± 10.7 years, and a mean SAPS II of 36 ± 10. Sur-
gical procedures consisted of 12 valves replacements, 12 cor-
onary grafts, and 5 mixed-procedure operations. All patients
were under mechanical ventilation at the start of the protocol,
five patients received inotropic support, three received vaso-
pressors, and five patients received vasodilators. Continuous
recording of CO data was performed over 1210 minutes per
patient (ranged from 1013 to 1454 minutes), allowing 12,099
simultaneous measurements to be obtained for each device
(417 ± 107 per patient). PAC-CCO measurements, consid-
ered as the reference values, ranged from 2.10 to 12.80 L/
minute (mean 4.86 ± 1.13 L/minute; Table 1). Comparison
results between the three methods are displayed in Table 1 for
global results.Available online http://ccforum.com/content/13/3/R73
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Accuracy and precision
After selection, 33 periods of very stable CO (PAC-CCO
slope > 10%, SD/mean < 20%, representing 4133 points and
34% of the database) were specifically analyzed in order to
minimize the effect of natural intra-patient CO variability and to
determine optimally bias and precision. Results are summa-
rized in Table 2. When all very stable CO values were aver-
aged for each patient, correlations of NICOM™ and Vigileo™
with PAC-CCO were 0.77 and 0.69, respectively (Figure 1).
The NICOM™ relative error was less than 30% in 94% of the
patients and less than 20% in 79%. The corresponding ratios
of the Vigileo™ were 91% and 79%, respectively (NS). The
variability of measurements around the trend line (precision)
was not different between the three methods: 8 ± 3%, 8 ±
4%, and 8 ± 3% for PAC-CCO, NICOM™, and Vigileo™,
respectively. In all cases, the variability around the trend line
was less than 20%. The bias of Vigileo™ was related to systo-
lic pressure (r2 = 0.19, P < 0.0001; Table 3). The bias of
NICOM™ was marginally related to pulmonary systolic arterial
pressure (r2 = 0.009, P < 0.04) and haemoglobin blood level
(r2 = 0.04, P < 0.001; Tables 4 and 5). We did not find any
other relationship between bias and any other factor.
Responsiveness
During acute hemodynamic challenges (19 patients; Table 6),
CO changes were 7.2 minutes faster with Vigileo™ and 6.9
minutes faster with NICOM™ (P < 0.05 both for NICOM™ and
Vigileo™ vs. PAC-CCO; NS for NICOM™ vs. Vigileo™). Ampli-
tude of changes was not significantly different than thermodi-
lution (Table 6).
Ability for detecting significant CO changes
We identified 37 periods of stable CO (PAC-CCO slope
within +/- 10% representing 39% of the database); averaged
slopes were 0.01 ± 0.06 for PAC-CCO, 0.03 ± 0.16 for
NICOM™, and 0.00 ± 0.17 for Vigileo™ (NS for all compari-
sons). Unacceptable differences in slope compared with the
reference were observed in two patients (5%) with the
NICOM™ and three patients with the Vigileo™ (8%).
During 33 periods of increasing CO (PAC slope > 10%, 29%
of the database), averaged slopes were 0.29 ± 0.21 for PAC-
CCO, 0.30 ± 0.24 for NICOM™, and 0.15 ± 0.20 for Vigileo™
(P < 0.05 for Vigileo™ vs. other). Unacceptable differences in
Table 1
Comparison between the three methods for all periods (global 
results)
Maximum Minimum Mean SD
CO value
PAC-CCO 12.8 2.1 4.9 1.8
NICOM™ 13.1 1.4 4.8*† 1.1
Vigileo™ 13.8 1.0 5.0 1.3
Differences in CO
Vigileo™ – PAC-CCO 8.9 -7.8 -0.1 1.2
NICOM™ – PAC-CCO 6.8 -6.3 0.1† 1.5
NICOM™ – Vigileo™ 8.6 -9.1 -0.1 1.8
Relative errors
Vigileo™ 1.97 0.0 0.19 0.17
NICOM™ 1.37 0.0 0.23† 0.18
Relative error = (tested CO – PAC-CCO)/PAC-CCO.
* P < 0.05 vs. PAC-CCO, † P < 0.05 for NICOM™ vs. Vigileo™
CO = cardiac output; SD = standard deviation.
Figure 1
Comparison between NICOM™ and Vigileo™ Comparison between NICOM™ and Vigileo™.  (Left panel) Relationship between averaged values of NICOM™ (in red, r = 0.77, not significant (NS) 
from identity line) and Vigileo™ (in black, r = 0,69, P < 0.05 from identity line) with PAC-CCO during periods of very stable cardiac output (CO). 
(Right panel) Corresponding Bland and Altman representation: NICOM™ bias = -0.01 L/min with limits of agreements (2 standard deviations) = 
1.68 L/min; Vigileo™ bias = -0.01 L/min with limits of agreements (2 standard deviations) = 1.62 L/min.Critical Care    Vol 13 No 3    Marqué et al.
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slope with the reference was observed in two cases (6%) with
the NICOM™ and four patients with the Vigileo™ (12%).
During 31 periods of decreasing CO (PAC-CCO slope <
10%, 31% of the database), averaged slopes were -0.29 ±
0.18 for PAC-CCO, 0.21 ± 0.26 for NICOM™, and 0.20 ±
0.31 for Vigileo™ (NS for all) An unacceptable difference of
slope with the reference was observed in four cases (13%)
with the NICOM™ and five patients with the Vigileo™ (16%).
Finally, the sensitivity and specificity for predicting significant
CO changes were 0.91 and 0.95, respectively, for the
NICOM™ and 0.86 and 0.92, respectively, for the Vigileo™.
Discussion
Although assessment of oxygen consumption (VO2) is limited
by numerous difficulties, rapid adaptation of VO2 to metabolic
needs remains conceptually one of the major objectives of
hemodynamic resuscitation [9-11]. By neglecting soluble
blood gases and considering the hemoglobin blood level as
normal and stable, VO2 is a direct function of only three varia-
bles: cardiac output (CO), arterial oxygen saturation (SaO2),
and mixed venous oxygen saturation (SvO2). The goal of
hemodynamic care can therefore be schematically described
as reaching and maintaining a specific combination of SaO2,
SvO2, and CO values to meet estimated metabolic needs.
Continuous and accurate monitoring of these three variables
is consequently of major interest for early detection of acute
events in any patient with or at risk for a compromised hemo-
dynamic situation.
This study shows that a totally non-invasive method of CO
monitoring can have the same performance as a moderately
invasive tool in postoperative high-risk patients. Our results
identify a negligible bias that is acceptable in 79% of individual
cases for both NICOM™ and Vigileo™ according to our own
restrictive tolerance criteria [5]. We considered a ± 20% tol-
erance because it is approximately the variability of the refer-
ence method [12-14]. Critchley and Critchley suggested that
a ± 30% limit of agreement was acceptable for CO measure-
ments [15]. However, this recommendation is based on limits
of agreements, on a central value from the average of the two-
tested technologies assuming that none of them is considered
as a reference. Then, the real difference between the two-
tested technologies may be more than 30%. Taking into con-
sideration this level of tolerance assumes that PAC-CCO is
not a reference and increases the accuracy of the Vigileo™ and
NICOM™ systems to 91% and 94%, respectively.
Even if controversial, PAC-CCO was taken as reference
because it remains the most widely used device for continuous
CO monitoring in many settings [8,16-18]. Fick [19] or bolus
thermodilution methods [14] could be considered as more
robust references for CO snapshot measurements but we
Table 2
Comparison between the three methods restricted to the very 
stable period
Maximum Minimum Mean SD
CO values
PAC-CCO 8.7 2.5 4.8 1.4
NICOM™ 10.2 2.1 4.8 1.4
FloTrac-Vigileo™ 11.2 1.0 5.0* 1.2
Differences in CO
Vigileo™ – PAC-CCO 4.8 -3.0 0.1 0.9
NICOM™ – PAC-CCO 5.3 -2.7 0.0† 1.0
NICOM™ – Vigileo™ 4.1 -5.1 -0.1 1.2
Relative errors
Vigileo™ 0.97 0.0 0.16 0.12
NICOM™ 1.15 0.0 0.17† 0.12
Relative error = (tested CO – PAC-CCO)/PAC-CCO.
* P < 0.05 vs. PAC-CCO, † P < 0.05 for NICOM™ vs. Vigileo™
CO = cardiac output; SD = standard deviation.
Table 3
Impact of systolic arterial pressure level on Vigileo™ accuracy
Systolic blood pressure Bias Relative error
> 160 mmHg 2.2 ± 1.5 L/min 51 ± 36%
120 to 160 mmHg 0.6 ± 1.2 L/min. 15 ± 27%
80 to 120 mmHg -0.1 ± 1.0 L/min -0.0 ± 21%
< 80 mmHg -0.9 ± 1.3 L/min -18 ± 25%
Table 4
Impact of pulmonary systolic arterial pressure level on 
NICOM™ accuracy
Pulmonary pressure Bias Relative error
> 50 mmHg 0.5 ± 1.3 L/min 12 ± 31%
40 to 50 mmHg, 0.4 ± 1.4 L/min 11 ± 30%
< 50 mmHg, 0.1 ± 1.5 L/min 4 ± 30%
Table 5
Impact of hemoglobin blood level on NICOM™ accuracy
Hemoglobin (gr/L) Bias Relative error
> 140 0.0 ± 1.0 L/min 1 ± 24%
100 to 140 0.3 ± 1.5 L/min 7 ± 30%
< 100 -0.3 ± 1.4 L/min -3 ± 28%Available online http://ccforum.com/content/13/3/R73
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were interested in comparing these new automatic and contin-
uous monitoring tools with a real equivalent monitoring refer-
ence. Using Fick or bolus thermodilution, it would have been
impossible to compare precision and responsiveness because
they require too much time due to manual data acquisition and
averaging of several measurements. In addition, we consid-
ered PAC-CCO as a reference for accuracy when the PAC-
CCO trend line slope was nearly flat and when the fluctuation
of measurements around this trend line slope was small, indi-
cating periods of CO stability. In such circumstances, the
standard error of the mean (SEM) is given by the formula SEM
= SD/√n. Even if PAC-CCO SD was 20%, the SEM was 2%
when 100 points are averaged during a period of stable CO
[20]. Then the lack of precision of the PAC-CCO can be com-
pensated by the time during which stable CO values are aver-
aged.
When studying a monitoring tool, precision and responsive-
ness may be of greater clinical importance than accuracy. The
precision of both Vigileo™ and NICOM™, the two-tested
devices, was similar and always clinically acceptable. The
responsiveness of both devices was faster than continuous
thermodilution and the amplitude responsiveness was not sig-
nificantly different. Finally, sensitivity and specificity for detect-
ing clinically relevant CO changes were good for both
NICOM™ and Vigileo™ by comparison with PAC-CCO.
A significant difference with the PAC-CCO trend line slope
was found in 5 to 13% of the cases for the NICOM™ and in 0
to 17% for the Vigileo™. In 21% of the patients, the bias was
more than 20% for both NICOM™ and Vigileo™. It is obvious
that several factors have artificially increased these propor-
tions of unacceptable response. First, even when using the
'STAT' button (that provides a quicker re-assessment of CO),
the PAC-CCO value is not really the averaged of one minute
of measurement but takes into considerations the past five
minutes. It results in a smoothing of acute CO changes and
could have impacted our results. Second, even when CO is
globally stable, the lag-time difference between NICOM™, Vig-
ileo™, and thermodilution may have created transient disagree-
ments in the minute-to-minute comparison. Third, results of the
NICOM™ and Vigileo™ are more likely to be transiently altered
by artifacts resulting from nurses' interventions and/or from
patient movements. Fourth, the software that was included in
the Vigileo™ device used in this study was the 1.01 version;
this software should be upgraded in the future, leading to a
potential improvement in its performances that will obviously
require further clinical assessment. Finally, our study was per-
formed on a selected population of postoperative cardiac
patients. Our results cannot be translated to a wider range of
clinical CO values, especially in high CO values and hyperdy-
namic states such as sepsis.
Conclusions
In this study, the clinical acceptability of CO monitoring using
a completely noninvasive technique (NICOM™) was equiva-
lent to the performance of a minimally invasive technique (Vig-
ileo™). The data was collected from postoperative cardiac
surgery patients, limited by the high proportion of males to
females, but included a wide range of CO values. According
to our predetermined criteria, accuracy was acceptable in a
large proportion of patients, precision was always clinically
acceptable, and responsiveness was faster than thermodilu-
tion. We believe that the noninvasive bioreactance technology,
considering its performance, should be added to the array of
CO monitoring tools in selected patients.
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Key messages
￿  NICOM™, a noninvasive cardiac output monitoring sys-
tem based on chest bioreactance, is equivalent to 
FloTrac-Vigileo™ in terms of accuracy, precision, time, 
and amplitude responsiveness.
Table 6
Responsiveness (time in minutes and amplitude in L) in 19 patients for which a hemodynamic challenge was performed
Time Amplitude
PAC-CCO NICOM™ Vigileo™ PAC-CCO NICOM™ Vigileo™
Negative 7.0 ± 2.6 1.3 ± 0.5* 1.1 ± 0.3* -2.9 ± 1.0 -2.3 ± 0.8 -1.8 ± 0.6
Positive 9.4 ± 4.9 1.4 ± 0.5* 1.1 ± 0.3* 2.0 ± 1.0 2.4 ± 1.4 1.8 ± 1.0
* P < 0.05
Negative challenges correspond to expected decrease in cardiac output and conversely for positive challenges.Critical Care    Vol 13 No 3    Marqué et al.
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